Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$6.56 USD
+0.13 (2.02%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.58 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.56 USD
+0.13 (2.02%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.58 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
Company News for Aug 17, 2020
by Zacks Equity Research
Companies in the news are: AMAT, MESO, NVAX, SKYS
Mesoblast Gets Favorable Votes From FDA Committee for Ryoncil
by Zacks Equity Research
Mesoblast (MESO) gets ODAC's vote in the ratio of 9:1 for GVHD drug.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
Pluristem Up on Cell Therapy Treatment of Coronavirus Patient
by Zacks Equity Research
Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
by Ekta Bagri
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.
Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Will Mesoblast Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Mesoblast
Zacks.com featured highlights include: China Distance Education, Intellicheck, Snap and Mesoblast
by Zacks Equity Research
Zacks.com featured highlights include: China Distance Education, Intellicheck, Snap and Mesoblast
4 Affordable Breakout Stocks for Stunning Returns
by Nitish Marwah
Selecting breakout stocks continues to be one of the most popular methods among active investors.
Zacks.com featured highlights include: CNX Midstream Partners LP, Akoustis Technologies, CRH Medical, Mesoblast and Photronics
by Zacks Equity Research
Zacks.com featured highlights include: CNX Midstream Partners LP, Akoustis Technologies, CRH Medical, Mesoblast and Photronics
5 Breakout Stocks for Explosive Returns
by Nitish Marwah
Picking breakout stocks is one of the most-favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.
Will Mesoblast Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Mesoblast.
Top Ranked Momentum Stocks to Buy for October 8th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 8th
Will Mesoblast Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Mesoblast.
Mesoblast Starts Rolling BLA Submission for Remestemcel-L
by Zacks Equity Research
Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.
3 Biotech Stocks With Rising Estimates in the Past Month
by Zacks Equity Research
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Caterpillar, Avon Products, JA Solar Holdings, Mesoblast and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Caterpillar, Avon Products, JA Solar Holdings, Mesoblast and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
3 Stocks Under $10 That Plummeted Today
by Benjamin Rains
At Zacks, we suggest that investors pay close attention to our proven stock-picking system, which stresses the importance of earnings estimate revisions in finding winning stocks. But we also understand that lower-priced stocks often make attractive investments, and we will always cover stocks that are making newsworthy moves, big or small.
Can the Rally in Mesoblast (MESO) Shares Continue?
by Zacks Equity Research
Mesoblast limited (MESO) has been on the move lately as the stock has risen by 20.6% in the past four weeks, and it is currently trading well above its 20-Day SMA
Mesoblast (MESO) Shares March Higher, Can It Continue?
by Zacks Equity Research
Mesoblast Limited (MESO) has been on the move lately as the stock has risen by 30.6% in the past four weeks, and it is currently trading well above its 20-Day SMA